Fig. 3

Evaluation by quantitative real-time PCR of mRNA expression of TRAP, CTSK, and MMP9 in a RAW 264.7 incubated, for 3 and 6 days, with MM1.S-derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml), rhRANKL (25 μg/ml), and rhAREG (50 μg/ml). b Human PB CD14⁺ cells incubated, for 6 days in osteoclastogenic medium (rhRANKL 25 ng/ml and MCSF 25 ng/m), with MM1.S derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (*p ≤ 0.05; ***p ≤ 0.001); ^#Exo+AREG mAb vs Exo (^#p ≤ 0.05). c MMP9 protein level was measured by ELISA in the conditioned medium of Human PB CD14⁺ cells incubated, for 6 days in osteoclastogenic medium (rhRANKL 25 ng/ml and MCSF 25 ng/m), with MM1.S-derived exosomes (50 μg/ml) treated or not with anti-AREG mAb (50 μg/ml). *Exo vs untreated (*p ≤ 0.05); ^#Exo+AREG mAb vs Exo (^#p ≤ 0.05). d Trap staining of Human PB CD14⁺ seeded in 96 well plates in presence or absence of MM1.S-derived exosomes (50 μg/ml) treated or not with mAb AREG and rhAREG anti-AREG mAb (50 μg/ml) for 6 days